期刊文献+

糖尿病肾病中过氧化物酶体增殖物激活受体作用的研究进展 被引量:1

下载PDF
导出
机构地区 大庆市第一医院
出处 《中国实验诊断学》 2005年第3期480-480,F003,共2页 Chinese Journal of Laboratory Diagnosis
  • 相关文献

参考文献10

  • 1Zhu Y, Qi C, Korenberg JR, et al. Structural organization of mouse peroxisome proliferator-activated receptor γ(mPPARγ) gene: alternative promoter use and different splicing yield two mPPARγ isoforms Proc [ J ].Natl Acad Sci, 1995,92:7921.
  • 2Willson TM, Cobb JE, Cowan DJ, et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones[ J ]. J Med Chem,1996,39:665.
  • 3Young BA, Johnson RJ, Alpers CE, et al. Cellular events in the evolution of experimental diabetic nephropathy[ J]. Kidney Int, 1995,47: 935.
  • 4Van Goor H, Van Der Horst MI, Fidler V, et al. Glomerular macrophage modulation affects mesangial expansion in the rat after renal ablation[J].Lab Invest, 1992,66:564.
  • 5Megyesi J, Price PM, Tamayo E, et al. The lack of a functional p21WAF1/CIP1gene ameliorates progression to chronic renal failure[J]. Proc Natl Acad Sci USA, 1999,96:10830.
  • 6FOGO AB: The role of angiotensin Ⅱ and plasminogen activator inhibitor-1 in progressive glomerulosclerosis[J]. Am J Kidney Dis, 2000,35:179.
  • 7Kruszynska YT, Yu JG, Olefsky JM, et al. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type2 diabetes and in lean and obese normal subjects[J]. Diabetes,2000,49:633.
  • 8Buckingham RE, Al-Barazanji KA, Toseland CD, et al. Peroxisome proliferator-activated receptor-gamme agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats[J].Diabetes, 1998,47:1326.
  • 9Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation[J].Nature, 1998,391:79.
  • 10Pardee AB. G1 events and regulation of cell proliferation[J]. Science,1989,246:603.

同被引文献27

  • 1张晓燕,陈丽红,管又飞.PPAR家族及其与代谢综合征的关系[J].生理科学进展,2005,36(1):6-12. 被引量:39
  • 2张超,管金发.过氧化物酶体增殖物激活受体γ与糖尿病肾病研究进展[J].内科理论与实践,2006,1(2):141-143. 被引量:2
  • 3黄洁丽,原爱红.过氧化物酶体增殖物激活受体γ与糖尿病肾病[J].第二军医大学学报,2006,27(12):1372-1374. 被引量:1
  • 4Young BA,Johnson RJ,Alpers CE,et al.Cellular events in the evolution of experimental diabetic nephropathy.Kidney Int,1995,47:935.
  • 5Megyesi J,Price PM,Tarnayo E,et al.The lack of a functional P21WAF1/CIP1 gene ameliorates progression to chronic renal failure.Proc Natl Acad SCI USA,1999,96:108 -130.
  • 6Lars Tatenhorst,EricHahnen,andMichaelT.HenekaPeroxisome Proliferator-Activated Receptors(PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors Hindawi Publishing Corporation PPAR Research,2008:9.
  • 7Jones JR,Barrick C,Kim KA,et al.Deletion of PPARγ in adipose tissue of mice protects against high fat diet induced obesity and insulin resistance,Proceedings of the National Academy of Sciences of the United States of America,2005,102 (17):6207-6212.
  • 8Weimin He PPARγ2Pro12Ala Polymorphism and Human Health.Hindawi Publishing Corporation PPAR Research,2009:15.
  • 9解汝娟,陈香美.PPARγ2基因多态性与疾病的关系.军医进修学院博士学位论文,2009:81-85.
  • 10Yen CJ,BeamerB A,NegriC,et al.Moleeular seanning of the human peroxisome proliferator 2 aetivated receptorγ(PPARγ) genein diabetie Caueasians:identifieation of a Prol2Ala PPARγ2 mutation.Bioehem BioPhys Res Comfnun,1997,241:270-274.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部